Crinetics stock maintains Buy rating at Jones Trading on positive ENDO'25 data

Crinetics Pharmaceuticals (CRNX) presented robust long-term data for its lead acromegaly drug, paltusotine, demonstrating sustained efficacy and reinforcing its commercial potential ahead of the September 25, 2025 PDUFA date. This positive data led multiple firms, including Jones Trading and JMP Securities, to reiterate Buy ratings, emphasizing the drug's market position and CRNX's broader pipeline, including atumelnant for CAH. However, analyst sentiment is mixed, with Goldman Sachs initiating a Neutral rating citing uncertainties around the drug's launch and addressable patient population.

Analysis

Crinetics Pharmaceuticals (CRNX) has presented compelling long-term efficacy and safety data for its lead drug candidate, paltusotine, for the treatment of acromegaly from its PATHFNDR-1 and PATHFNDR-2 open-label extension studies. The data, which demonstrates sustained IGF-1 level control for over a year, significantly strengthens the drug's commercial profile ahead of its September 25, 2025 PDUFA date, potentially positioning it as a strong competitor to existing injectable therapies. This positive clinical outlook is reflected in bullish analyst sentiment from firms like Jones Trading and JMP Securities, which have reiterated Buy ratings with price targets of $71.00 and $90.00, respectively. JMP Securities notably assigns a 90% probability of approval. However, this optimism is tempered by Goldman Sachs' recent initiation of coverage with a Neutral rating and a $36.00 price target, citing uncertainties around the drug's commercial launch and the size of its addressable patient population. Beyond its lead asset, the company is advancing its pipeline with promising Phase 2 data for atumelnant in congenital adrenal hyperplasia (CAH) and a preclinical asset for Graves' Disease, supported by a strong balance sheet reported to have more cash than debt.

Key Decisions for Investors

• Investors should treat the September 25, 2025 PDUFA date for paltusotine as the primary near-term catalyst, representing a significant binary event for Crinetics' valuation.
• It is crucial to weigh the substantial upside potential, reflected in analyst price targets as high as $97, against the execution risks highlighted by Goldman Sachs, specifically uncertainties surrounding the commercial launch and market penetration.
• Monitor progress in the broader pipeline, particularly the planned initiation of pivotal Phase 3 trials for atumelnant in 2025, as successful advancement would de-risk the company's reliance on paltusotine and validate its drug discovery platform.
• Given the company's strong balance sheet with more cash than debt, immediate financing risk is low, providing a stable runway to achieve upcoming clinical and regulatory milestones.